XML 62 R8.htm IDEA: XBRL DOCUMENT v2.4.0.8
BUSINESS SEGMENT INFORMATION
 12 Months Ended
Dec. 31, 2013
Segment Reporting [Abstract]  
Segment Reporting Disclosure [Text Block]
Note 2. BUSINESS SEGMENT INFORMATION
BMS operates in a single segment engaged in the discovery, development, licensing, manufacturing, marketing, distribution and sale of innovative medicines that help patients prevail over serious diseases. A global research and development organization and supply chain organization are responsible for the development and delivery of products to the market. Regional commercial organizations are used to distribute and sell the product. The business is also supported by global corporate staff functions. Segment information is consistent with the financial information regularly reviewed by the chief executive officer for purposes of evaluating performance, allocating resources, setting incentive compensation targets, and planning and forecasting future periods.
Products are sold principally to wholesalers, and to a lesser extent, directly to distributors, retailers, hospitals, clinics, government agencies and pharmacies. Gross revenues to the three largest pharmaceutical wholesalers in the U.S. as a percentage of global gross revenues were as follows:
 
 
2013
 
2012
 
2011
McKesson Corporation
 
19
%
 
23
%
 
26
%
Cardinal Health, Inc.
 
14
%
 
19
%
 
21
%
AmerisourceBergen Corporation
 
15
%
 
14
%
 
16
%

Selected geographic area information was as follows:
 
 
Total Revenues
 
Property, Plant and Equipment
Dollars in Millions
 
2013
 
2012
 
2011
 
2013
 
2012
United States
 
$
8,318

 
$
10,384

 
$
14,039

 
$
3,708

 
$
4,464

Europe
 
3,930

 
3,706

 
3,879

 
729

 
740

Rest of the World
 
3,295

 
3,204

 
3,237

 
142

 
129

Other(a) 
 
842

 
327

 
89

 
—

 
—

Total
 
$
16,385

 
$
17,621

 
$
21,244

 
$
4,579

 
$
5,333


(a)
Other total revenues include royalties and other alliance-related revenues for products not sold by our regional commercial organizations.
Total revenues of key products were as follows:
 
 
Year Ended December 31,
Dollars in Millions
 
2013
 
2012
 
2011
Virology
 
 
 
 
 
 
Baraclude (entecavir)
 
$
1,527

 
$
1,388

 
$
1,196

Reyataz (atazanavir sulfate)
 
1,551

 
1,521

 
1,569

Sustiva (efavirenz) Franchise(a)
 
1,614

 
1,527

 
1,485

Oncology
 
 
 
 
 
 
Erbitux* (cetuximab)
 
696

 
702

 
691

Sprycel (dasatinib)
 
1,280

 
1,019

 
803

Yervoy (ipilimumab)
 
960

 
706

 
360

Neuroscience
 
 
 
 
 
 
Abilify* (aripiprazole)(b)
 
2,289

 
2,827

 
2,758

Metabolics
 
 
 
 
 
 
Bydureon* (exenatide extended-release for injectable suspension)
 
298

 
78

 
N/A

Byetta* (exenatide)
 
400

 
149

 
N/A

Forxiga (dapagliflozin)
 
23

 
—

 
N/A

Onglyza/Kombiglyze (saxagliptin/saxagliptin and metformin)
 
877

 
709

 
473

Immunoscience
 
 
 
 
 
 
Nulojix (belatacept)
 
26

 
11

 
3

Orencia (abatacept)
 
1,444

 
1,176

 
917

Cardiovascular
 
 
 
 
 
 
Avapro*/Avalide* (irbesartan/irbesartan-hydrochlorothiazide)
 
231

 
503

 
952

Eliquis (apixaban)
 
146

 
2

 
—

Plavix* (clopidogrel bisulfate)
 
258

 
2,547

 
7,087

 
 
 
 
 
 
 
Mature Products and All Other
 
2,765

 
2,756

 
2,950

Total Revenues
 
$
16,385

 
$
17,621

 
$
21,244


(a)
Includes $1,366 million in 2013, $1,267 million in 2012 and $1,203 million in 2011 presented in alliance and other revenue.
(b)
Includes $1,840 million in 2013, $2,340 million in 2012 and $2,303 million in 2011 presented in alliance and other revenue.